© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, BridgeBio Pharma, Inc. (BBIO) shows an Average True Range (ATR) of 2.54 and an Enterprise Value of 5.98B. Its average trading volume over the past 3 months is 2.22M, indicating liquidity. These fundamental metrics provide insight into BBIO's underlying financial health and market activity.
BridgeBio Pharma, Inc. (BBIO) technical indicators as of December 22, 2025: the SMA 20 is 4.4%, SMA 50 at 15.99%, and SMA 200 at 58.61%. The RSI 14 value is 66.52, suggesting its current momentum. These technical analysis signals help assess BBIO's price trends and potential future movements.
BridgeBio Pharma, Inc. (BBIO) stock performance overview as of December 22, 2025: The 52-week high is $77.2 (currently -0.27% below), and the 52-week low is $26.55 (currently 201.1% above). Over the past year, BBIO's performance is 177.56%, compared to the S&P 500's 12.87% change.
According to market data, BridgeBio Pharma, Inc. (BBIO) stock's recent performance metrics show that over the last month, BBIO is 16.33%, with a Year-to-Date (YTD) performance of 178.06%. Over the past year, the stock has seen a 177.56% change. These figures summarize BBIO's price movements across various periods, reflecting its historical returns.
According to current financial data, BBIO stock's P/E (TTM) ratio is -18.24, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for BBIO, including P/S (41.09), P/B (-7.56), and P/FCF (-24.67), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.